"Vaginal rejuvenation" is a marketing umbrella, not a single medical procedure. The energy-based devices sold under that name — fractional CO₂ lasers like MonaLisa Touch and radiofrequency devices like ThermiVa — are promoted for vaginal dryness, "laxity," painful sex, and mild urinary leaking, usually at $500–$1,000-plus per session and almost never covered by insurance.[5] Here is the part the ads leave out: the U.S. Food and Drug Administration has not cleared or approved any of these devices for those uses, the best-designed trial found no benefit over a fake (sham) treatment, and the FDA has logged real harms including burns, scarring, and lasting pain.[1]
If your goal is relief from the very real changes menopause brings, there are cheaper, better-proven options worth trying first. This article is a reference to help you weigh the claims and go in informed — not a diagnosis or a substitute for your own clinician.
What "vaginal rejuvenation" actually means
"Vaginal rejuvenation" is a catch-all for cosmetic and functional promises, delivered through two main energy-based technologies:
- Fractional CO₂ laser (e.g., MonaLisa Touch, FemTouch, diVa). A probe delivers microscopic columns of heat to the vaginal wall, meant to trigger collagen remodeling. It is typically sold as a course of three sessions plus annual "maintenance," so the real cost is a multiple of the per-session price.[5]
- Radiofrequency (RF) (e.g., ThermiVa, Votiva). A wand uses radio waves to heat the tissue, again usually across three sessions.
Clinics market these devices for the symptoms of genitourinary syndrome of menopause (GSM) — vaginal dryness, irritation, painful sex, recurrent UTIs, and mild urinary incontinence — alongside vaguer promises of "tightening" or a more youthful appearance. GSM is genuinely common, affecting an estimated 27–84% of women after menopause, and it is badly under-treated.[3] That large unmet need is exactly what makes an expensive, under-tested procedure easy to sell.
The FDA warning: these devices are not cleared for this
On July 30, 2018, the FDA issued a safety communication and notified seven manufacturers — Alma Lasers, BTL Aesthetics, BTL Industries, Cynosure, InMode, Sciton, and Thermigen — about inappropriate marketing. That position has not been reversed. Three points matter:
- The FDA has not cleared or approved any energy-based device to perform vaginal "rejuvenation," to treat vaginal laxity, or to treat symptoms related to menopause, sexual function, or urinary incontinence.[1]
- These lasers are cleared for narrow gynecologic jobs — destroying abnormal or pre-cancerous cervical and vaginal tissue and treating genital warts — not for the wellness uses they are advertised for. A device being "FDA-cleared" for one thing does not make it approved for menopause symptoms.[1]
- The FDA called the marketing "deceptive" and, reviewing adverse-event reports and published literature, flagged specific harms: vaginal burns, scarring, pain during sex, and recurring or chronic pain.[1]
The agency singled out marketing aimed at women who had finished breast-cancer treatment and were in early menopause — told a device could fix symptoms that other therapies might otherwise address — as especially troubling.[1]
What the evidence actually shows
Most of the positive data behind these devices comes from uncontrolled studies: everyone receives the laser, symptoms are rated before and after, and any improvement is credited to the device. That design cannot separate a genuine effect from placebo — and placebo effects are large for intimate, subjective symptoms, especially after several attentive clinic visits. Much of this research is also industry-funded. When researchers run the harder test — a double-blind, sham-controlled trial, where some women unknowingly receive a deactivated probe — the apparent benefit tends to disappear.
The landmark example is a 2021 trial published in JAMA: 85 postmenopausal women were randomized to fractional CO₂ laser or an identical-feeling sham and followed for 12 months. The laser did not improve symptoms more than the sham. Symptom-severity scores actually fell slightly more in the placebo group (a change of −26.6 versus −17.2, where a bigger drop is better), quality-of-life scores showed no meaningful difference, and tissue biopsies looked the same between groups.[2] Later sham-controlled trials and pooled analyses have echoed this pattern. A 2023 meta-analysis of seven sham-controlled trials, for example, found no advantage for the laser on sexual function, pain during sex, or objective vaginal-health measures, and only a modest edge on a single patient-rated symptom score — far from the transformation the marketing implies.[6] And note what those trials tested: nearly all of the controlled evidence is on lasers. Radiofrequency devices such as ThermiVa and Votiva have been studied mostly in small, uncontrolled series with no long-term sham comparison, so the case for them is thinner still — not stronger.
That is why the major bodies land where they do. The Menopause Society concludes there is insufficient placebo-controlled evidence to judge the efficacy or safety of laser and energy-based devices for GSM, and does not recommend them as established treatment.[3] The American Urogynecologic Society — which wrote a consensus statement precisely because strong trial evidence is lacking — urges caution until well-designed studies exist.[4]
| Marketing claim | What the evidence shows | FDA status |
|---|---|---|
| Reverses vaginal dryness / GSM | Best sham-controlled trial found no benefit over a placebo procedure at 12 months; specialty societies say the evidence is insufficient. | Not cleared or approved for menopause symptoms. |
| "Tightens" or rejuvenates the vagina, fixes laxity | No high-quality controlled evidence; "rejuvenation" is a marketing term, not a medical diagnosis or measurable outcome. | Not cleared; FDA has called such marketing deceptive. |
| Relieves painful sex | Uncontrolled studies suggest improvement, but sham-controlled trials do not confirm benefit above placebo. | Not cleared for sexual function. |
| Treats mild urinary incontinence | Limited, low-quality data; societies advise against routine use outside clinical trials. | Not cleared for urinary incontinence. |
| Safe, quick, "no downtime" | FDA logged burns, scarring, painful sex, and chronic pain; safety has not been established for these uses. | Reported adverse events; safety not established. |
Proven, lower-cost options to try first
For GSM, the well-evidenced first-line steps cost a small fraction of a laser course:
- Vaginal moisturizers and lubricants. Regular-use moisturizers rehydrate the tissue over time; lubricants ease friction during sex. Both are inexpensive, available over the counter, and recommended as first-line by menopause specialists.[3] See our guide to choosing a vaginal moisturizer.
- Low-dose vaginal estrogen. A prescription cream, tablet, or ring that delivers a small amount of estrogen directly to vaginal tissue is among the best-studied treatments for GSM. It is clinician-led — something to discuss with your provider rather than start or stop on your own. Learn more about vaginal estrogen.
- Other prescription options such as vaginal DHEA inserts and oral ospemifene, which a clinician can weigh against your personal and family history.[3]
- Pelvic floor physical therapy. If mild urinary leaking is part of what a laser is being sold to fix, supervised pelvic floor muscle training is a proven, low-risk first step for stress and urge incontinence — treating the cause rather than heating tissue. A clinician or pelvic-floor physiotherapist can tailor a program to you.
Pairing these with an open conversation about intimacy often resolves symptoms — see sex after menopause, and our broader vaginal health and menopause hubs.
When to see a doctor
Book a medical visit — and hold off on any laser consult until you have — if you notice any of the following:
- Any bleeding after menopause. Postmenopausal bleeding is never normal and needs prompt evaluation to rule out serious causes; see postmenopausal bleeding. Do not let a cosmetic clinic explain it away.
- New pelvic pain, a vaginal bulge or pressure, or urinary leaking that disrupts daily life — these have specific, treatable causes worth diagnosing properly.
- Persistent dryness, burning, or painful sex despite regular moisturizer use — a clinician can confirm GSM and discuss prescription options.
- Symptoms after an energy-based treatment: worsening pain, burns, or scarring warrant urgent review.
To find a menopause-literate clinician, start with find care. This article is a reference, not a diagnosis.
Questions to ask before you book
- Is this device FDA-cleared or approved for my specific symptom — or only cleared for a different, unrelated use? (For GSM and "rejuvenation," the honest answer is no.)
- What sham-controlled evidence supports it for my symptom, and who funded those studies?
- Have I tried the proven first-line options — moisturizers, lubricants, and a conversation about vaginal estrogen — yet?
- What are the odds of burns, scarring, and worsening pain, and how would you manage them?
- What is the total cost, including "maintenance" sessions, and is any of it refundable if it does not work?
The honest verdict
Vaginal rejuvenation lasers are expensive, under-evidenced, and FDA-flagged. The symptoms they target are real and treatable — but the strongest studies say the device itself works no better than a convincing placebo, while the risks are concrete. Try the proven, cheaper options first. If you still consider an energy-based device afterward, go in with the questions above and a clinician who has no financial stake in the sale.
